Resultados da pesquisa - Portal para modelos de dados médicos (portal MDM)

Filtrar os resultados da pesquisa
Selecionar modelos de dados

Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

83 Resultados da pesquisa.

GSK Hepatitis A Vaccine ADDITIONAL VACCINATION Tracking Document Long Term Follow-up NCT00291876

- 24/08/2017 - 1 Formulário, 3 Grupos de itens, 11 Elementos de dados, 1 Idioma

Grupos de itens: Study administration, Long Term Follow-up, Investigator

Study ID: 100571 (M138) Clinical Study ID: 100571 Study Title: Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00291876 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 4 Study Recruitment Status: Completed Generic Name: Hepatitis A Vaccine, Inactivated Trade Name: Havrix Study Indication: Hepatitis A https://clinicaltrials.gov/ct2/show/NCT00291876

Rotterdem Symptom Checklist (RSCL) Week 36 Mepolizumab HES NCT00086658 - Rotterdem Symptom Checklist (RSCL) Week 36

- 15/07/2017 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma

Grupo de itens: Symptom checklist

Study part: Rotterdem Symptom Checklist (RSCL) Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Dose 1: GSK DTPa vaccine (Infanrix) 100484 - Study ID: 100484 Dose 1

- 19/06/2017 - 1 Formulário, 1 Grupo de itens, 91 Elementos de dados, 1 Idioma

Grupo de itens: Solicited Adverse Events - Local Symptoms

Study ID: 100484 Clinical Study ID: 100484 (DTPa) Study Title: An open prospective study of immunogenicity and reactogenicity of DTPa vaccine (Infanrix) given as a booster to healthy school children 10 to 12 years of age Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 4 Study Recruitment Status: Completed Generic Name: Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed Trade Name: BIO DTPA (INFANRIX); Infanrix Study Indication: Acellular Pertussis; Diphtheria; Tetanus; acellular pertussis Documentation: Dose 1

Joint findings physical therapy UKM - Joint findings

- 16/06/2017 - 1 Formulário, 2 Grupos de itens, 14 Elementos de dados, 2 Idiomas

Grupos de itens: Patient demographics, Range of motion

Joint findings form converted to ODM format. Routine documentation of University Hospital of Münster. Publication granted by Dirk Robrecht

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 2 Visit 8 (Week 15) RLS Episode 1

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma

Grupos de itens: General Information, PRN Subject Diary, Study Medication

Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 2: Visit 8 (Week 15) RLS Episode 1 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 15: Visit 3 (Week 5) RLS Episode 3

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma

Grupos de itens: General Information, PRN Subject Diary, Study Medication

Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 15: Visit 3 (Week 5) RLS Episode 3 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 27: Visit 4 (Week 7) RLS Episode 4

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma

Grupos de itens: General Information, PRN Subject Diary, Study Medication

Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 27: Visit 4 (Week 7) RLS Episode 4 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 21: Visit 3 (Week 5) RLS Episode 9

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma

Grupos de itens: General Information, PRN Subject Diary, Study Medication

Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 21: Visit 3 (Week 5) RLS Episode 9 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 25: Visit 4 (Week 7) RLS Episode 2

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma

Grupos de itens: General Information, PRN Subject Diary, Study Medication

Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 25: Visit 4 (Week 7) RLS Episode 2 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 22: Visit 3 (Week 5) RLS Episode 10

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma

Grupos de itens: General Information, PRN Subject Diary, Study Medication

Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 22: Visit 3 (Week 5) RLS Episode 10 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 24: Visit 4 (Week 7) RLS Episode 1

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma

Grupos de itens: General Information, PRN Subject Diary, Study Medication

Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 24: Visit 4 (Week 7) RLS Episode 1 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 26: Visit 4 (Week 7) RLS Episode 3

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma

Grupos de itens: General Information, PRN Subject Diary, Study Medication

Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 26: Visit 4 (Week 7) RLS Episode 3 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.